Iridex Reports First Quarter 2025 Financial Results

About this update from Iridex Corporation

[{"type":"image","alt":"IRIDEX Corporation","displaySize":"","headline":null,"caption":"IRIDEX Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r51WXqBBd3BbgLab_DBobg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ffe273cdb8e913085b9d4a020e219250","width":300,"height":90}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025.","length":351,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Highlights","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter","length":150,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarter","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Sold 24 Cyclo G6 Glaucoma Laser Systems compared to 22 in the prior year quarter","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false}]},{"val":[{"type":"text","content":"Retina product revenue was $6.6 million, compared to $6.8 million in the prior year quarter","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced operating expense by 32% compared to the prior year period","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased adjusted EBITDA to $0.4 million, an improvement of $2.9 million compared to adjusted EBITDA loss of $2.5 million in the prior year quarter","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened balance sheet through a strategic inv...

More updates from Iridex Corporation